Bobby is a world-renowned scientist and physician and accomplished strategic and organizational leader with more than 25 years of experience in medicine and biotechnology. He is co-founder and chief executive officer of Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe. Bobby has been a pioneer in gene therapy and the evolution of hematopoietic stem cell (HSC) gene therapy —including some of the first studies in patients with severe primary immune deficiencies — bringing it from bench side research into late-stage clinical trials and demonstrating that gene therapy can potentially cure severe genetic diseases. He has led Orchard through the approval of Lib/Lenmeldy in the EU and USA for the treatment of metachromatic leukodystrophy (MLD). His unparalleled expertise and deep relationships with key physicians and treatment centers around the world are integral to Orchard’s efforts to identify patients with MLD and other severe genetic conditions through targeted disease education, early diagnosis and comprehensive newborn screening. In 2024, he was named in the TIME 100 inaugural list of most influential people in global health.

Bobby is an honorary professor of pediatrics and immunology at the UCL Great Ormond Street Institute of Child Health. He studied medicine and surgery at Kings College in London before completing his Ph.D. at the UCL Great Ormond Street Institute of Child Health